GP
GP
FACULTY OF SCIENCE
DEPARTMENT OF CHEMISTRY
YEAR : TWO
SEMESTER: ONE
QUESTION
Introductiong
Glycogen is the main storage form of glucose and it is stored in the liver and skeletal
muscles in the body. It serves as a reservoir of energy that can be mobilized in times of need
such as during fasting. Glycogen phosphorylase is the enzyme responsible for glycogen
breakdown in the liver and muscles. It catalyses the rate limiting step in glycogenolysis in
animals by releasing glucose-1-phosphate from the terminal alpha-1, 4-glycosidic bond. This
process is crucial for maintaining blood glucose levels during fasting and for providing
an essential cofactor, pryridoxal phosphate (PLP), for its activity. The enzyme can be found in
two different states, glycogen phosphorylase a (GPa) and glycogen phosphorylase b (GPb). The
difference in the structures is due to phosphorylation Ser-14 residue which results in the active
form GPa. Protein phosphatases dephosphorylates the GPa to the in active form GPb. Both forms
of glycogen phosphorylase can also be found in T and R states where T is the tense form because
it appears to have a low affinity for a substrate and R is the relaxed form where it appears to have
LITERATURE REVIEW
Various advances in understanding Glycogen Phosphorylase (GP) regulation have provided
significant insights into its role in energy homeostasis, particularly under conditions of exercise
and metabolic disorders. Gonzalez et al. (2016) explored how acute and chronic exercise
influences GP activity in skeletal muscles. Their study emphasized that GP is highly responsive
demands. The findings also demonstrated that consistent physical training improves the
exertion.
Further investigations by Meyer et al. (2018) focused on the enzyme’s allosteric regulation. This
study highlighted AMP’s role in stabilizing the R state of GP, thereby enhancing glycogenolysis
under low energy conditions. It revealed how AMP binding increases GP’s sensitivity to
Zhang et al. (2020) explored the relationship between GP dysregulation and metabolic diseases,
particularly Type 2 Diabetes. Their research identified that impaired GP activity contributes to
glycogen build-up and insulin resistance in skeletal muscle. This study brought attention to GP
as a potential therapeutic target for improving glucose metabolism and insulin sensitivity,
Huang et al. (2022) used molecular dynamics simulations to delve deeper into GP’s structural
changes upon binding with allosteric effectors such as AMP and ATP. Their study showed how
AMP binding induces an open, active conformation of GP, facilitating glycogen breakdown,
while ATP binding stabilizes a closed, inactive conformation. This study provided a more
detailed understanding of how GP transitions between active and inactive states, illustrating the
This regulation occurs through two primary mechanisms; allosteric regulation and covalent
modification.
cyclic AMP (cAMP) signaling pathways initiated by hormones like glucagon and epinephrine.
Dephosphorylation; when blood glucose levels rise after a meal, insulin is released, activating
protein phosphatase-1 (PP1) that dephosphorylates phosphorylase a back to its less active form
phosphorylase b. This activity decreases glycogen breakdown favouring storage rather than
release of glucose.
Allosteric regulation;
This allows for a rapid response to the cell’s energy status by sensing levels of specific
metabolites.
Allosteric activation
In muscle cells when energy levels are low, AMP concentration increases. AMP acts as an
allosteric activator for phosphorylase b, promoting its conversion from the T state to the R state.
This transition enhances its activity and allows for increased glycogen breakdown to meet energy
demands.
Allosteric inhibition
When energy levels are high, glycogen phosphorylase is inhibited allosterically by ATP and
glucose-6-phosphate. These molecules bind to the specific allosteric sites on the enzyme,
inducing conformational changes that reduce its activity and decreases affinity for glycogen
substrate. ATP-mediated inhibition prevents phosphorylase kinase activation while glucose-6-
HOMEOSTASIS
Glycogen phosphorylase catalyses the release of glucose-s1-phosphate from the alpha-1,4 non
of GP is covalently attached to the enzyme through a Schiff base linkage with a Lysine (K)
residue.
When glycogen phosphorylase binds with glycogen, a free inorganic phosphate anion is
positioned by the PLP and the enzyme active site ,in proximity with the anomeric carbon
position of the non reducing end residue of the glycogen residue. The oxygen involved in the
glycosidic bond attacks the partially charged hydrogen associated with the phosphate ion leading
to the cleavage of the glycosidic bond. The cleaved glycogen chain leaves the active site and one
of the phosphate oxygens attacks the carbocation intermediate created during the cleavage.
This results in the release of terminal glucose residue as glucose-1-phophosphate.
HOW CHANGES IN ENERGY STATUS, HORMONAL SIGNALS AND ALLOSTERIC
ENERGY STATUS
The cell’s energy status, is primarily indicated by the levels of ATP and AMP, directly
High Energy (High ATP Levels): When the cell has sufficient energy, ATP acts as an allosteric
inhibitor of Glycogen Phosphorylase, stabilizing the enzyme in the less active T state. This
Low Energy (High AMP Levels): When energy is low, AMP levels rise, and AMP binds to
Glycogen Phosphorylase b, shifting it to the R state, which has a higher affinity for glycogen.
ALLOSTERIC EFFECTORS
Allosteric effectors play a crucial role in regulating the activity of glycogen phosphorylase by
influencing its conformation and consequently its ability to bind to glycogen and catalyse its
ALLOSTERIC ACTIVATORS
Adenosine Monophosphate (AMP): AMP binds to the allosteric site of glycogen phosphorylase
b. this binding induces a conformational change, shifting the enzyme from the tense state to the
relaxed state. In the relaxed state glycogen phosphorylase enzyme has a higher affinity for its
substrate glycogen. This results in enhanced glycogenolysis, allowing the rapid mobilisation of
ALLOSTERIC INHIBITORS
phosphate.
Inhibition by ATP
When energy levels are sufficient, ATP levels rise and serves as a signal that the cell does not
require additional energy from glycogen breakdown. ATP binds to the allosteric site on glycogen
phosphorylase, stabilizing the tense state. This prevents the transition to the relaxed state and
decreases enzyme activity. As a result the affinity of GP for glycogen is reduced, leading to
When glycolytic pathways are active and energy is being produced, glucose-6-phosphate levels
rise. It binds to the allosteric site of GP inducing a conformational change that further stabilises
HORMONAL SIGNALS
During fasting, the levels of glucose in blood are low, glucagon hormone is released and then it
receptor), activating adenylate cyclase and increasing cAMP, which activates protein kinase A
(PKA). PKA phosphorylates and activates phosphorylase kinase which in turn phosphorylates
During strenuous exercise, epinephrine also known as adrenaline is released, it binds to the G-
protein receptor which is related to the glucagon receptor. However, it’s specific for epinephrine
and cannot bind with glucagon. It then activates the G-protein pathway leading to protein kinase
activation which then phosphorylates and activates glycogen phosphorylase kinase which in turn
phosphorylates and activates glycogen phosphorylase thus increasing the rate of enzyme activity.
However, when sugar levels are high, insulin hormone is released into the blood, it promotes
Conclusion
both glucose release and energy homeostasis. Its regulation involves complex interactions
between hormonal signals, allosteric effectors, and covalent modifications, ensuring that
glycogen is broken down only when necessary. This multi-faceted regulation allows the enzyme
to respond dynamically to changes in energy status, providing the body with the glucose it needs
binding and its effects on enzyme kinetics.” Biochemical Journal, 475(16), 2581-2592.
3. Zhang, M., et al. (2020). “Glycogen phosphorylase and its role in type 2 diabetes:
Implications for therapy.” Diabetes Research and Clinical Practice, 166, 108290.
4. Huang, Y., et al. (2022). “Structural dynamics of glycogen phosphorylase: Insights from